<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04360655</url>
  </required_header>
  <id_info>
    <org_study_id>Surpass</org_study_id>
    <nct_id>NCT04360655</nct_id>
  </id_info>
  <brief_title>Bronchoscopic Microwave Intervention Treatment in Advanced Central NSCLC</brief_title>
  <official_title>A Randomized, Prospective Study of the Efficacy and Safety of the 1st Treatment in Advanced Central NSCLC by PD-1/PD-L1 Inhibitor and Chemotherapy With/Without Bronchoscopic Microwave Intervention</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Shanghai Pulmonary Hospital, Shanghai, China</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Shanghai Pulmonary Hospital, Shanghai, China</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      A randomized, prospective study of the efficacy and safety of the first-line treatment in
      advanced central non-small cell lung cancer patients by anti-PD-1 / PD-L1 monoclonal antibody
      and chemotherapy versus anti-PD-1 / PD-L1 monoclonal antibody and chemotherapy combined with
      bronchoscopic microwave intervention
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      This study is a randomized, prospective study, which will analyze the efficacy and safety of
      the first-line treatment in advanced central non-small cell lung cancer patients by anti-PD-1
      / PD-L1 monoclonal antibody and chemotherapy versus anti-PD-1 / PD-L1 monoclonal antibody and
      chemotherapy combined with bronchoscopic microwave intervention. The efficacy will include
      objective response rate, disease control rate, progression-free survival, and overall
      survival. The safety will include adverse events and quality of life.
    </textblock>
  </detailed_description>
  <overall_status>Not yet recruiting</overall_status>
  <start_date type="Anticipated">May 1, 2020</start_date>
  <completion_date type="Anticipated">May 1, 2023</completion_date>
  <primary_completion_date type="Anticipated">April 30, 2022</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>objective response rate</measure>
    <time_frame>6 weeks</time_frame>
    <description>objective response rate</description>
  </primary_outcome>
  <primary_outcome>
    <measure>progression-free survival</measure>
    <time_frame>1 years</time_frame>
    <description>progression-free survival</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>disease control rate</measure>
    <time_frame>6 weeks</time_frame>
    <description>disease control rate</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>overall survival</measure>
    <time_frame>2 years</time_frame>
    <description>overall survival</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>adverse events</measure>
    <time_frame>3 weeks</time_frame>
    <description>adverse events</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>quality of life score</measure>
    <time_frame>World Health Organization Quality of Life Scale-Brief (WHOQOL-BREF)score 0-100ï¼Œhigher scores mean a better outcome.</time_frame>
    <description>quality of life score</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">50</enrollment>
  <condition>Effect Increased</condition>
  <condition>Safety Issues</condition>
  <arm_group>
    <arm_group_label>anti-PD-1 / PD-L1 monoclonal antibody and chemotherapy</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>anti-PD-1 / PD-L1 monoclonal antibody and chemotherapy</description>
  </arm_group>
  <arm_group>
    <arm_group_label>combined with bronchoscopic microwave intervention</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>anti-PD-1 / PD-L1 monoclonal antibody and chemotherapy combined with bronchoscopic microwave intervention</description>
  </arm_group>
  <intervention>
    <intervention_type>Procedure</intervention_type>
    <intervention_name>bronchoscopic microwave intervention</intervention_name>
    <description>bronchoscopic microwave intervention</description>
    <arm_group_label>combined with bronchoscopic microwave intervention</arm_group_label>
    <other_name>Local treatment</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>anti-PD-1 / PD-L1 monoclonal antibody and chemotherapy</intervention_name>
    <description>anti-PD-1 / PD-L1 monoclonal antibody and chemotherapy</description>
    <arm_group_label>anti-PD-1 / PD-L1 monoclonal antibody and chemotherapy</arm_group_label>
    <arm_group_label>combined with bronchoscopic microwave intervention</arm_group_label>
    <other_name>Systemic treatment</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  advanced central non-small cell lung cancer patients, untreated, tolerating
             bronchoscopy

        Exclusion Criteria:

          -  contraindications to tracheoscopy, chemotherapy, and immunotherapy
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>75 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Caicun Zhou, MD, PHD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Shanghai Pulmonary Hospital, Shanghai, China</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Yayi He</last_name>
    <phone>862165115006</phone>
    <phone_ext>3056</phone_ext>
    <email>doctorjael@foxmail.com</email>
  </overall_contact>
  <verification_date>April 2020</verification_date>
  <study_first_submitted>April 20, 2020</study_first_submitted>
  <study_first_submitted_qc>April 22, 2020</study_first_submitted_qc>
  <study_first_posted type="Actual">April 24, 2020</study_first_posted>
  <last_update_submitted>April 22, 2020</last_update_submitted>
  <last_update_submitted_qc>April 22, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">April 24, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Shanghai Pulmonary Hospital, Shanghai, China</investigator_affiliation>
    <investigator_full_name>Caicun Zhou</investigator_full_name>
    <investigator_title>Director, Head of Oncology, Principal Investigator, Clinical Professor</investigator_title>
  </responsible_party>
  <keyword>anti-PD-1 / PD-L1 monoclonal antibody</keyword>
  <keyword>chemotherapy</keyword>
  <keyword>bronchoscopic microwave intervention</keyword>
  <keyword>advanced central non-small cell lung cancer patients</keyword>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Antibodies</mesh_term>
    <mesh_term>Antibodies, Monoclonal</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

